Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications.
Cytek Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$24.40|
|52 Week High||US$17.40|
|52 Week Low||US$28.70|
|1 Month Change||5.86%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||30.06%|
Recent News & Updates
|CTKB||US Life Sciences||US Market|
Return vs Industry: Insufficient data to determine how CTKB performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how CTKB performed against the US Market.
Stable Share Price: CTKB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: Insufficient data to determine CTKB's volatility change over the past year.
About the Company
Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
Cytek Biosciences Fundamentals Summary
|CTKB fundamental statistics|
Is CTKB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CTKB income statement (TTM)|
|Cost of Revenue||US$41.10m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.066|
|Net Profit Margin||1.83%|
How did CTKB perform over the long term?See historical performance and comparison
Is Cytek Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CTKB ($24.4) is trading above our estimate of fair value ($2.25)
Significantly Below Fair Value: CTKB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CTKB is poor value based on its PE Ratio (1634.3x) compared to the US Life Sciences industry average (52.2x).
PE vs Market: CTKB is poor value based on its PE Ratio (1634.3x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTKB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTKB has negative assets, so we can't compare its PB Ratio to the US Life Sciences industry average.
How is Cytek Biosciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CTKB's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if CTKB's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CTKB's revenue (23.2% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: CTKB's revenue (23.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CTKB's Return on Equity is forecast to be low in 3 years time (4.8%).
How has Cytek Biosciences performed over the past 5 years?
Last years revenue growth
Earnings and Revenue History
Quality Earnings: CTKB has high quality earnings.
Growing Profit Margin: CTKB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CTKB's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CTKB's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: CTKB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (56.9%).
Return on Equity
High ROE: CTKB's Return on Equity (8.1%) is considered low.
How is Cytek Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: CTKB's short term assets ($216.9M) exceed its short term liabilities ($28.2M).
Long Term Liabilities: CTKB's short term assets ($216.9M) exceed its long term liabilities ($18.8M).
Debt to Equity History and Analysis
Debt Level: CTKB is debt free.
Reducing Debt: CTKB had no debt 5 years ago.
Debt Coverage: CTKB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CTKB has no debt, therefore coverage of interest payments is not a concern.
What is Cytek Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTKB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTKB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTKB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTKB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTKB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wenbin Jiang (57 yo)
Dr. Wenbin Jiang, Ph D., is co-founder and President of Cytek Biosciences, Inc and has been its Chief Executive Officer and Director since December 2014. Dr. Jiang is a seasoned entrepreneur and inventor....
CEO Compensation Analysis
Compensation vs Market: Wenbin's total compensation ($USD422.22K) is below average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Insufficient data to compare Wenbin's compensation with company performance.
Experienced Management: CTKB's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: CTKB's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CTKB insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CTKB only recently listed within the past 12 months.
Cytek Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Cytek Biosciences, Inc.
- Ticker: CTKB
- Exchange: NasdaqGS
- Founded: 2014
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.197b
- Shares outstanding: 135.18m
- Website: https://cytekbio.com
Number of Employees
- Cytek Biosciences, Inc.
- 46107 Landing Parkway
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:08|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.